Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its ordinary shares represented by American depositary shares for up to an aggregate amount of $500 million. The American depositary shares are listed on the Nasdaq Global Select Market under the symbol “BNTX.”

BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate David Li. The tax team included counsel Ethan R. Goldman and associate Alexander J. Hendin. The intellectual property and technology transactions team included partner Pritesh P. Shah and associates Tilak Koilvaram and Yana Kipnis. All members of the Davis Polk team are based in the New York office.